Retatrutide Peptide is a once-weekly triple receptor agonist that simultaneously activates GIP, GLP-1, and glucagon (GCGR) receptors. Its mechanism aims to superimpose three metabolic pathways: the GLP-1/GIP side promotes insulin secretion, suppresses appetite, and delays gastric emptying; the GCGR side may increase fatty acid oxidation and energy expenditure, thus achieving a "multi-point drive" in weight loss and metabolic improvement. The pharmacokinetic half-life is approximately 6 days.
Shaanxi Medibridge has been supplying peptides for research purposes to various research institutes and universities in recent years. Currently, as a peptide manufacturer, we can guarantee a purity of over 99.7% for our long peptides, and endotoxin control and heavy metal indicators meet relevant international standards.
COA
Specifications (for research use only)
|
Form |
Sample Order |
Specification |
|
Raw powder |
1 g |
Purity is NLT 99.75% |
|
Vials |
10 vials |
3ml/5ml/7ml/15ml vials etc. |
Scientific Research Sector
Mechanism of Action
Retatrutide peptides act simultaneously on GIPR, GLP-1R, and GCGR. The GLP-1/GIP pathway primarily suppresses appetite, delays gastric emptying, and enhances insulin secretion in hyperglycemic states; moderate activation of glucagon receptors is expected to increase fatty acid oxidation and energy expenditure. With a molecular half-life of approximately 6 days, it supports a weekly dosing rhythm. The overall design aims to achieve a dual effect of "controlled intake + increased expenditure" to obtain deeper signals of weight and metabolic improvement.
Phase 2 Outcomes
In obese subjects without diabetes, weight loss reached a maximum of approximately 24% at 48 weeks (high-dose titration), with significant weight loss targets achieved at ≥10% and ≥15%. In individuals with type 2 diabetes, HbA1c decreased by a maximum of approximately 2 percentage points at 24 weeks, accompanied by approximately 16–17% weight loss at 36 weeks. Regarding the liver, MRI-PDFF showed an average reduction of approximately 80% in liver lipids relative to baseline, with nearly 90% of the high-dose group achieving <5% liver lipids at 48 weeks. Multidimensional outcomes showed good consistency, but long-term maintenance, post-discontinuation changes, and adverse outcomes require further investigation.
Safety & Tolerability
The most common adverse reactions are gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation, etc.), which are mostly mild to moderate and dose-related. A low starting point and slow escalation can improve tolerability and reduce discontinuation. Resting heart rate increases slightly from baseline, usually peaking around week 24 and then gradually decreasing; monitoring during titration and maintenance is recommended. Due to its glucose-dependent insulinotropic effect, the risk of hypoglycemia as a monotherapy is relatively low; individualized assessment and attention to insulin/sulfonylurea dose adjustments are necessary when used in combination with other hypoglycemic agents. Current safety information is primarily based on Phase II data and requires further validation through larger-scale and longer-term follow-ups.
Hepatic Outcomes (MRI-PDFF)
MRI-PDFF showed a significant decrease in liver lipids, with some subjects reaching the "liver lipids <5%" threshold at 24–48 weeks. Improved liver lipids were correlated with weight loss, relief of insulin resistance, and reduction in triglycerides. Current analysis did not show a clear increase in drug-induced severe hepatotoxicity signals; however, due to sample size and follow-up time limitations, further histological and long-term clinical outcomes (inflammation, fibrosis, events) are needed for validation. Imaging endpoints are sensitive and easily quantifiable, suitable as early indicators, but do not replace pathological and hard outcomes.
Synthetic Scheme
Shaanxi Medibridge is a Retatrutide peptide supplier. We provide a Retatrutide synthesis scheme for reference by various research institutions to facilitate mutual learning.
Below is a high‑level, research‑oriented synthetic scheme for LY3437943 (a long, acylated tri‑agonist peptide) suitable for method planning and documentation. It is intentionally sequence‑agnostic and does not reproduce proprietary details; adapt to your lab SOPs and the exact sequence/linker used.
Modality: A single-chain peptide (≈35-45 aa) engineered for balanced GIP/GLP-1/GCGR agonism, with N-terminal DPP-4 resistance (e.g., Aib at position 2 in many incretin analogs) and a single lipidation site (ε-Lys) to extend half-life.
Overall strategy: Fmoc/tBu solid-phase peptide synthesis (SPPS) on an amide resin → orthogonal Lys deprotection → on-resin linker/lipidation → N-terminal treatment → global cleavage/deprotection → reverse-phase purification → analytical release → lyophilized product.
FAQ
Q: Is Shaanxi Medibridge a peptide supplier, or does it only supply Retatrutide?
A: Of course, we are a peptide manufacturer managed according to GMP standards. We can customize peptides with any identifiable sequence.
Q: Is the Retatrutide we purchased high purity?
A: Yes, we can provide this product with a purity of at least 99.75%. Some other smaller companies can only control the purity to between 98.5% and 99.1%.
Q: What is the product's positioning and purpose?
A: LY3437943 (research grade) is a long-acting peptide of the triple receptor agonist class, for research use only (RUO). It can be used for in vitro experiments, method development, analytical control, etc.
Q: Do you have third-party testing?
A: Of course, each batch undergoes testing by JANOSHIK or Chromate. We also support customers in having third-party testing done on every batch of products they purchase.
Q: Will you resend my goods after they are detained by customs?
A: Of course, this condition is the most basic guarantee for our customers. However, our logistics channels are excellent; our shipments have only been detained three times in a year. Even if goods are detained, we will reschedule them.
Q: How should I store the peptides after I receive the goods?
A: Store in the dark at -20°C to -80°C; avoid repeated freeze-thaw cycles.
Q: After I receive the vial, how do I dissolve it?
A: Reconstitution recommendations: Slowly dissolve in sterile buffer (such as an aqueous system containing a small amount of acid/salt) at the target concentration; if necessary, use a small amount of coagulant (pH/ionic strength/small amount of organic phase) and perform a small-scale evaluation; keep the temperature low and limit the usage window during use.
If you are looking for a high-quality Retatrutide peptide manufacturer with whom you can establish a long-term, stable partnership, then Shaanxi Medibridge Biotech Co., Ltd. would be your best business partner. Don't hesitate to contact us at hi@medibridgeapi.com.
Hot Tags: retatrutide peptide, China retatrutide peptide manufacturers, suppliers, factory, Pt 141 Peptide Powder, Retatrutide Peptide, Selank Powder, Semax Peptide, Tirzepatide for Weight Loss, Vasoactive Intestinal Peptide Powder
